Prevalence of Underlying Conditions Among COVID-19 Patients Prevalence of Underlying Conditions Among COVID-19 Patients

Preliminary data indicates that persons with underlying health conditions such as diabetes, CVD, and chronic lung disease appear to be at higher risk for severe COVID-19-associated disease.Morbidity &Mortality Weekly Report
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news

Related Links:

Authors: Bartels SJ, Baggett TP, Freudenreich O, Bird BL Abstract People with serious mental illness are at disproportionate risk of COVID-19 morbidity and mortality because of high rates of risk factors that directly parallel those related to poor coronavirus outcomes, including smoking, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes, along with housing instability, homelessness, food insecurity, and poverty. Community-based behavioral health organizations are also at risk of adverse outcomes because of dramatic declines in revenues and a diminished workforce. The State of Massachusett...
Source: Psychiatric Services - Category: Psychiatry Tags: Psychiatr Serv Source Type: research
By Cecilia RussellMILAN, Italy, Jun 4 2020 (IPS) The COVID-19 pandemic has highlighted the inherent fragility of food systems, Marta Antonelli told an international video conference organised by the Barilla Center for Food Nutrition (BCFN). However, she said, it also offered an opportunity to reset the way food is produced, distributed and consumed. The pandemic disrupted the food system, triggering food insecurity and resulted in sharp increases in the cost of food – up to 10 per cent in sub-Saharan Africa. Jobs were lost, children who received one meal a day at school lost access to this source of nutrition, and ...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Development & Aid Economy & Trade Education Featured Food & Agriculture Global Globalisation Headlines Health Humanitarian Emergencies Natural Resources Poverty & SDGs TerraViva United Nations Barilla Center for Food and Nutritio Source Type: news
             Basel, 04 June 2020   - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirm ed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Bigfoot Biomedical hasn't let the coronavirus pandemic stand in the way of bringing its injection-based digitized insulin dosing platform to the U.S. market. If anything, CEO Jeffrey Brewer says the pandemic has "only crystalized the need for medical solutions like ours that facilitate remote care, remote support, and home delivery." The company has raised a total of $55 million to close its series C equity financing. Abbott led the round with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, and Cormorant Asset Management, along with n...
Source: MDDI - Category: Medical Devices Tags: Business R & D Source Type: news
Publication date: Available online 2 June 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Amerta Ghosh, Bhavya Arora, Ritesh Gupta, Shajith Anoop, Anoop Misra
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Publication date: Available online 2 June 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Timur Ekiz, Ahmet Cemal Pazarlı
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Publication date: September–October 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 14, Issue 5Author(s): Hema S. Gopalan, Anoop Misra
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Have type 1 diabetes and being forced to work during the pandemic? Here are the legal resources to know about.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs
Fractyl Laboratories is seeking to ‘turn back the clock’ in Type 2 diabetes progression with its disease-modifying therapy. FDA granted the Lexington, MA-based company IDE to launch a pivotal trial of the Revita DMR, a which holds the potential to eliminate the need for insulin injections in patients suffering from Type 2 diabetes. “Insulin is a challenging drug for patients with Type 2 diabetes because it can cause weight gain,” Harith Rajagopalan M.D. Ph.D., co-founder and CEO of Fractyl told MD+DI. “It can cause a risk of your bloo...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Regulatory and Compliance Source Type: news
Some things you may need to know.  Nothing last week as I was " on holiday " , so two weeks'worth this time.COVID-19A systematic scoping review of COVID-19 during pregnancy and childbirth (International Journal of Obstetrics and Gynecology)ResearchProgression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis (BMJ)**Leicester authors**Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis (PLoS Medicine)Maternal cardiovas...
Source: Browsing - Category: Databases & Libraries Tags: midwifery Source Type: blogs
More News: COVID-19 | Diabetes | Endocrinology | Health | International Medicine & Public Health